 |
 |
Date Announced: 25 Jul 2013
Optical biopsy firm adds distributors in North America, Taiwan, Italy, Israel and Eastern Europe.
PARIS--(Marketwired - Jul 25, 2013) - Mauna Kea Technologies (NYSE Euronext: MKEA), leader in the optical biopsy market and developer of Cellvizio®, the fastest way to see cancer, has entered several distribution agreements for its line of Cellvizio LAB products, including the Cellvizio Dual Band, for pre-clinical research.
With new partnerships in place in North America, Taiwan, Italy, Israel and Eastern Europe, Cellvizio LAB is now actively marketed to research laboratories in more than 25 countries.
Quorum Technologies Inc., a North American leader in confocal microscopy and advanced in vivo imaging techniques, will distribute the full range of Cellvizio LAB systems and products, including the Cellvizio Dual Band, to research laboratories in the United States and exclusively in Canada.
"Cellvizio LAB represents a major step forward in the evolution of microscopic imaging, which has evolved from in vitro views of fixed tissue to long-term observation of cultured cells and now to a high-resolution view of cells in the very best environmental system available, the living animal," said Jeff Butler, confocal imaging specialist at Quorum Technologies.
"With Cellvizio LAB added to our portfolio, we are able to offer our customers the most comprehensive set of tools and software platforms to support the in vitro and in vivo imaging needs of scientific and medical researchers."
The Cellvizio Dual Band is Mauna Kea Technologies' latest innovation in animal imaging that provides structural and functional information about living tissues inside the animal's body in real time and in several colors.
Mauna Kea Technologies also announced key Cellvizio LAB distribution partnerships with Cold Spring Biotech Corp. in Taiwan; Crisel Instruments in Italy; Biotech Europe in Central and Eastern Europe; and Merkel Technologies in Israel.
"We selected these new distribution partners for their high-quality customer networks in high-growth markets that include top-tier research laboratories, pharmaceutical companies and some of the most innovative biotech companies in the industry," commented Sacha Loiseau, CEO of Mauna Kea Technologies. "We're so pleased that much of the global scientific community now has access to Cellvizio Dual Band technology which will continue to be the key driver of our pre-clinical sales."
Source: Mauna Kea Technologies
E-mail: via web site
Web Site: www.maunakeatech.com
| © 2024 SPIE Europe |
|
